CD19 and lymphoma: CD19-directed CAR T-cells engineered to constitutively express CD40 ligand (CD40L, CD145) were demonstrated to have increased tumor clearance in a xenograft model of CD19+ lymphoma, increased CAR T-cell proliferation, as well as increased the secretion of pro-inflammatory Th1 cytokines (118).